Literature DB >> 10946028

Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction.

R Choussat1, G Montalescot, J Collet, C Jardel, A Ankri, A Fillet, D Thomas, J Raymond, J Bastard, G Drobinski, J Orfila, H Agut, D Thomas.   

Abstract

Inflammation and chronic infections may be important features in the pathogenesis of acute coronary syndromes. We describe 6 systemic markers of inflammation in patients with unstable angina or non-Q-wave myocardial infarction and the relations between these markers, seropositivity to chronic infections, and prognosis. C-reactive protein (CRP), serum amyloid A protein (SAA), fibrinogen, interleukin-6 (IL-6), neopterin, procalcitonin, and serum antibody levels to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus were measured on admission and 48 hours later. One-year clinical follow-up was performed. Plasma levels of acute phase reactants were all elevated on admission and increased further at 48 hours: CRP from 10.1 +/- 2.1 mg/L at baseline to 26.6 +/- 5.1 mg/L at 48 hours (p <0.001); SAA from 27.3 +/- 8.5 to 93.1 +/- 23.2 mg/dl (p <0.005); fibrinogen from 3.2 +/- 0.1 to 3.8 +/- 0.1 g/L (p <0.0001); whereas initial high levels of IL-6 tended also to increase from 9.8 +/- 2 to 15.3 +/- 3.1 pg/ml (p = NS). In contrast, neopterin and procalcitonin remained unchanged. We found no association between levels of each inflammatory marker and the serologic status. Furthermore, levels of inflammatory proteins in patients seronegative to all 3 agents were comparable to those of patients seropositive to 2 or 3 infectious agents. The composite end points of death, myocardial infarction, recurrent angina, or revascularization at 1-year follow-up did not differ according to the serologic status. Thus, in patients with acute coronary syndromes, the acute phase proteins increased over the first 2 days of hospitalization. This initial inflammatory reaction as well as the 1-year clinical outcome did not differ according to the initial serologic status of Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946028     DOI: 10.1016/s0002-9149(00)00950-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 2.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  Seroprevalence of antibodies to microorganisms known to cause arterial and myocardial damage in patients with or without coronary stenosis.

Authors:  C Stöllberger; G Mölzer; J Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

4.  Changes in the relative inflammatory responses in sheep cells overexpressing of toll-like receptor 4 when stimulated with LPS.

Authors:  Shoulong Deng; Qian Wu; Kun Yu; Yunhai Zhang; Yuchang Yao; Wenting Li; Zhuo Deng; Guoshi Liu; Wu Li; Zhengxing Lian
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

5.  Prognostic role of Helicobacter pylori infection in acute coronary syndrome: a prospective cohort study.

Authors:  R Eskandarian; R Ghorbani; M Shiyasi; B Momeni; K Hajifathalian; M Madani
Journal:  Cardiovasc J Afr       Date:  2012-04       Impact factor: 1.167

6.  Effect of Different Pollution Parameters and Chemical Components of PM2.5 on Health of Residents of Xinxiang City, China.

Authors:  Shuang Wang; Mandeep Kaur; Tengfei Li; Feng Pan
Journal:  Int J Environ Res Public Health       Date:  2021-06-25       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.